The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma.

ABSTRACT:

Background

Meningiomas are the most common tumor arising within the cranium of adults. Despite surgical resection and radiotherapy, many meningiomas invade the brain, and many recur, often repeatedly. To date, no chemotherapy has proven effective against such tumors. Thus, there is an urgent need for chemotherapeutic options for treating meningiomas, especially those that enhance radiotherapy. Palbociclib is an inhibitor of cyclin-dependent kinases 4 and 6 that has been shown to enhance radiotherapy in preclinical models of other cancers, is well-tolerated in patients, and is used to treat malignancies elsewhere in the body. We, therefore, sought to determine its therapeutic potential in preclinical models of meningioma.

Methods

Patient-derived meningioma cells were tested <

SUBMITTER: Horbinski C 

PROVIDER: S-EPMC8325754 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature